AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24933729 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed performance index for insole materials
Number of subjects: 0
Study 22294737 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation (fish oil capsules providing 900 mg of n-3 LCPUFA daily)
Number of subjects: 706
Study 22294737 — intervention group
Group type: COMPARATOR
Intervention: Control (matched vegetable oil capsules without n-3 LCPUFA)
Number of subjects: 706
Study 18802718 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3% buffered hypertonic seawater
Number of subjects: 45
Study 18802718 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered isotonic saline solution
Number of subjects: 45
Study 18802718 — intervention group
Group type: COMPARATOR
Intervention: Non-buffered isotonic saline
Number of subjects: 45
Study 16551896 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day opioid weaning using oral methadone
Number of subjects: 0
Study 16551896 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day opioid weaning using oral methadone
Number of subjects: 0
Study 12923131 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and Mifepristone (600 mg given orally)
Number of subjects: 212
Study 12923131 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and Placebo
Number of subjects: 212
Study 12923131 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and Mifepristone (600 mg given orally) with progesterone level >/=10 ng/l
Number of subjects: 212
Study 12923131 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and Placebo with progesterone level >/=10 ng/l
Number of subjects: 212
Study 10942740 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 67
Study 10942740 — intervention group
Group type: COMPARATOR
Intervention: VDD pacing
Number of subjects: 67
Study 8775573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise glycerol hydration (1.2 gm/kg glycerol in 26 ml/kg solution)
Number of subjects: 18
Study 8775573 — intervention group
Group type: COMPARATOR
Intervention: Pre-exercise placebo hydration (26 ml/kg of aspartame flavored water)
Number of subjects: 18
Study 1428611 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrasonic inserts
Number of subjects: 10
Study 1428611 — intervention group
Group type: COMPARATOR
Intervention: Unmodified ultrasonic inserts
Number of subjects: 10
Study 1428611 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 10
Study 3972529 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 105
Study 3972529 — intervention group
Group type: COMPARATOR
Intervention: metrizoate
Number of subjects: 105
Study 3972529 — intervention group
Group type: EXPERIMENTAL
Intervention: both
Number of subjects: 105
Study 30716446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 hours (q12h)
Number of subjects: 1199
Study 30716446 — intervention group
Group type: COMPARATOR
Intervention: Ceftaroline fosamil 600 mg every 8 hours (q8h)
Number of subjects: 1199
Study 30390706 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive standardized strategy (interval evaluation and stepwise selection for laparoscopic cholecystectomy)
Number of subjects: 0
Study 30390706 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard practice according to physician's knowledge and experience)
Number of subjects: 0
Study 30390706 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive standardized strategy
Number of subjects: 0
Study 30390706 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27178144 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation of breast target
Number of subjects: 0
Study 27178144 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25005331 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein pre-load (50 g whey in 250 ml water)
Number of subjects: 15
Study 25005331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml water)
Number of subjects: 15
Study 22887019 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 at 10 or 20 mg/kg doses
Number of subjects: 24
Study 22887019 — intervention group
Group type: EXPERIMENTAL
Intervention: HQK-1001 at 30 mg/kg/day
Number of subjects: 24
Study 22887019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20103538 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence in the PACU
Number of subjects: 300
Study 20103538 — intervention group
Group type: COMPARATOR
Intervention: Parent absent in the PACU
Number of subjects: 300
Study 20103538 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence or absence in the PACU
Number of subjects: 300
Study 20103538 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <5 years
Number of subjects: 300
Study 20103538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Children's Hospital of Eastern Ontario Pain Scale score at 15 minutes after arrival
Number of subjects: 300
Study 20103538 — intervention group
Group type: COMPARATOR
Intervention: Parent absent group
Number of subjects: 300
Study 18631246 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD) applied during access flap surgery
Number of subjects: 39
Study 18631246 — intervention group
Group type: COMPARATOR
Intervention: Access flap surgery without EMD
Number of subjects: 39
Study 16133954 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg/day
Number of subjects: 10
Study 16133954 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 4 mg/day
Number of subjects: 10
Study 16133954 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 6 mg/day
Number of subjects: 10
Study 16133954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11896377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-setting
Number of subjects: 114
Study 11896377 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 114
Study 11896377 — intervention group
Group type: COMPARATOR
Intervention: Light exercise therapy
Number of subjects: 114
Study 10396858 — intervention group
Group type: COMPARATOR
Intervention: I-131 therapy
Number of subjects: 408
Study 10396858 — intervention group
Group type: EXPERIMENTAL
Intervention: I-131 therapy + external beam radiotherapy (RT)
Number of subjects: 408
Study 7554308 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter)
Number of subjects: 63
Study 1974505 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily for 4 weeks
Number of subjects: 118
Study 1974505 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily for 4 weeks
Number of subjects: 118
Study 1974505 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily + HCTZ 25 mg once daily for 10 weeks
Number of subjects: 118
Study 1974505 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily + HCTZ 25 mg once daily for 10 weeks
Number of subjects: 118
Study 6116461 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (0.5 mg/ml)
Number of subjects: 90
Study 6116461 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.05 mg/ml)
Number of subjects: 90
Study 31813332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (MP)
Number of subjects: 0
Study 31813332 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 0
Study 31813332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (MP) alone
Number of subjects: 0
Study 31097414 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention (eight sessions of individual problem-solving therapy, with an extra two to four sessions if needed) plus enhanced usual care
Number of subjects: 1178
Study 31097414 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care only
Number of subjects: 1178
Study 28256070 — intervention group
Group type: EXPERIMENTAL
Intervention: ProNutrients® Probiotic powder sachet containing BB-12 and LGG
Number of subjects: 0
Study 28256070 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented control group
Number of subjects: 0
Study 25874938 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) on specific acupoints
Number of subjects: 63
Study 25874938 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupressure (SAA) on non-specific acupoints
Number of subjects: 63
Study 23691203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 240
Study 23691203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 240
Study 23691203 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study 21048041 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX-B (capecitabine, oxaliplatin, and bevacizumab)
Number of subjects: 279
Study 21048041 — intervention group
Group type: EXPERIMENTAL
Intervention: Beneficial genetic profile (TYMS enhancer region and VEGF +405G>C polymorphisms)
Number of subjects: 279
Study 21048041 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable genetic profile (not specified)
Number of subjects: 279
Study 21048041 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX-B
Number of subjects: 279
Study 19265317 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program for 16 weeks
Number of subjects: 70
Study 17101741 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 (15 mg/mL) during 12 hours
Number of subjects: 24
Study 17101741 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 12800796 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 0
Study 12800796 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 12800796 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 12800796 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy and radiation
Number of subjects: 0
Study 12800796 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal treatment
Number of subjects: 0
Study 12800796 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 0
Study 11155057 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil hydrochloride, bolus doses of 1 microgram/kg followed by continuous infusions of 0.1‐0.5 microgram/kg/min, titrated to effect.
Number of subjects: 2
Study 9124202 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (arm A)
Number of subjects: 10
Study 9124202 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF followed by GM‐CSF (arm B)
Number of subjects: 10
Study 8268729 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766
Number of subjects: 24
Study 8268729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8268729 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical function testing and myometry
Number of subjects: 24
Study 3703481 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta) eye drops
Number of subjects: 20
Study 3703481 — intervention group
Group type: COMPARATOR
Intervention: Iododesoxyuridine eye drops
Number of subjects: 20
Study 29095347 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoon-fed amino acid-based formula (AAF) with a yogurt-type texture (group 1)
Number of subjects: 0
Study 29095347 — intervention group
Group type: COMPARATOR
Intervention: Reference oral liquid formula (Neocate) (group 2)
Number of subjects: 0
Study 26373657 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal care (telephone-based counseling and nicotine replacement therapy for 12 months)
Number of subjects: 0
Study 26373657 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard 8-week treatment)
Number of subjects: 0
Study 24639438 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention based on WHO/UNICEF Baby‐Friendly Hospital Initiative
Number of subjects: 31
Study 24639438 — intervention group
Group type: COMPARATOR
Intervention: Standard practices (control group)
Number of subjects: 31
Study 24639438 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 31
Study 22464164 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 preload (500 mL)
Number of subjects: 60
Study 22464164 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution preload (1000 mL)
Number of subjects: 60
Study 20040880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise training
Number of subjects: 0
Study 20040880 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise training
Number of subjects: 0
Study 20040880 — intervention group
Group type: EXPERIMENTAL
Intervention: High relative intensity exercise training
Number of subjects: 0
Study 17618447 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 40
Study 17618447 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 40
Study 17618447 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment
Number of subjects: 40
Study 16117771 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) instilled locally before implant placement
Number of subjects: 10
Study 16117771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 10
Study 12324668 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rhDNase (2.5 mg once daily)
Number of subjects: 48
Study 12324668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day rhDNase (2.5 mg every other day)
Number of subjects: 48
Study 12324668 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (5 ml 7% HS twice daily)
Number of subjects: 48
Study 12324668 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rhDNase
Number of subjects: 48
Study 12080402 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (12.5% of energy from walnuts, 44-58 g/day)
Number of subjects: 40
Study 12080402 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 40
Study 9733272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) at a dose of 50 mg/kg daily infused intravenously over 1 hour for 4 days (in aplastic anemia patients)
Number of subjects: 16
Study 9733272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) at a dose of 60 mg/kg by i.v. infusion over 1 hour daily for 2 days followed by total body irradiation (in leukemia patients)
Number of subjects: 16
Study 9733272 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed hemorrhagic cystitis (HC)
Number of subjects: 16
Study 9733272 — intervention group
Group type: COMPARATOR
Intervention: Rest of the patients (without HC)
Number of subjects: 16
Study 8296403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent suction and pressure (Vacusac treatment)
Number of subjects: 22
Study 8296403 — intervention group
Group type: COMPARATOR
Intervention: Placebo applications
Number of subjects: 22
Study 3180634 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 7
Study 3180634 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 7
Study 3180634 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 7
Study 3180634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29453785 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-soaked gauze
Number of subjects: 60
Study 29453785 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinse
Number of subjects: 60
Study 28202500 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention comprising Macmillan's 'Move More' information, a short motivational interview recommending to walk for at least 30 minutes on alternate days and attend a volunteer-led group walk weekly.
Number of subjects: 42
Study 28202500 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study 26144276 — intervention group
Group type: EXPERIMENTAL
Intervention: Log book (LB) support for secondary prevention (SP) after acute MI (LB+ group)
Number of subjects: 183
Study 24122045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120
Study 24122045 — intervention group
Group type: COMPARATOR
Intervention: Unipolar hemiarthroplasty
Number of subjects: 120
Study 21508653 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane supplemented with remifentanil (group SR)
Number of subjects: 50
Study 21508653 — intervention group
Group type: COMPARATOR
Intervention: Low-flow sevoflurane (group S)
Number of subjects: 50
Study 18675597 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial aspiration before saline infusion sonography (SIS)
Number of subjects: 113
Study 18675597 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion sonography (SIS) before endometrial aspiration
Number of subjects: 113
Study 16427019 — intervention group
Group type: EXPERIMENTAL
Intervention: Street-level advertisements (SLAs)
Number of subjects: 0
Study 16427019 — intervention group
Group type: COMPARATOR
Intervention: Raised-level advertisements (RLAs)
Number of subjects: 0
Study 12867217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 375 mg PO, dexamethasone 20 mg PO, ondansetron 32 mg IV on day 1, followed by aprepitant 250 mg PO and dexamethasone 8 mg PO on days 2 through 5
Number of subjects: 37
Study 12867217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg PO with granisetron 2 mg PO on day 1, followed by aprepitant 80 mg PO on days 2 and 3
Number of subjects: 37
Study 12867217 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 20 mg PO and ondansetron 32 mg IV on day 1, followed by dexamethasone 8 mg PO on days 2 through 5
Number of subjects: 37
Study 12867217 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 2 mg PO on day 1 only
Number of subjects: 37
Study 11152085 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment in advance
Number of subjects: 583
Study 11152085 — intervention group
Group type: COMPARATOR
Intervention: Payment on completion
Number of subjects: 583
Study 11152085 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 583
Study 11152085 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of timing of incentives
Number of subjects: 583
Study 11152085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 583
Study 9194649 — intervention group
Group type: EXPERIMENTAL
Intervention: 2, 4 or 8 mg of micronized MENT (single i.m. injections)
Number of subjects: 42
Study 9194649 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 2 or 4 mg of MENT (six consecutive daily i.m. injections)
Number of subjects: 42
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous medication
Number of subjects: 121
Study 1587077 — intervention group
Group type: COMPARATOR
Intervention: Targeted intermittent medication
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward dose adjustment
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial beneficial effect (greater than or equal to 6 months of weight loss greater than or equal to 10% from baseline)
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at week 160
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at week 190
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout successes
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropouts with initial benefit
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal benefit in dropouts
Number of subjects: 121
Study 1587077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropouts in study less than 1 year
Number of subjects: 121
Study 30732920 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided surgery group
Number of subjects: 60
Study 30732920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 28285608 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index (GI) breakfast
Number of subjects: 40
Study 28285608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) breakfast
Number of subjects: 40
Study 28285608 — intervention group
Group type: COMPARATOR
Intervention: Both high and low GI breakfasts
Number of subjects: 40
Study 25229641 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries resin infiltration
Number of subjects: 0
Study 25229641 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF) application
Number of subjects: 0
Study 25229641 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23886736 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for anxiety
Number of subjects: 1004
Study 21359903 — intervention group
Group type: EXPERIMENTAL
Intervention: INtraoperative Video‐Enhanced Surgical Training (INVEST)
Number of subjects: 10
Study 21359903 — intervention group
Group type: COMPARATOR
Intervention: Master‐Apprentice Model (MAM)
Number of subjects: 10
Study 19638205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain frequency and severity (measured using 24 item Geriatric Pain Measure)
Number of subjects: 406
Study 19638205 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulties with basic ADLs
Number of subjects: 406
Study 19638205 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk for social isolation (measured using 6 item Lubben Social Network scale)
Number of subjects: 406
Study 19638205 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic education only
Number of subjects: 406
Study 16393295 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 0
Study 16393295 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) >25%
Number of subjects: 0
Study 15242436 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% nitrous oxide
Number of subjects: 344